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Abstract
Background: The common cold and other viral airway infections are highly prevalent in the population, and their
treatment often requires the use of medications for symptomatic relief. Paracetamol is as an analgesic and
antipyretic; chlorphenamine is an antihistamine; and phenylephrine, a vasoconstrictor and decongestant. This
randomized, double-blind, placebo-controlled trial sought to evaluate the efficacy and safety of a fixed-dose
combination of paracetamol, chlorphenamine and phenylephrine in the symptomatic treatment of the common
cold and flu-like syndrome in adults.
Methods: This study enrolled 146 individuals aged 18 to 60 years who had moderate to severe flu-like syndrome or
common cold. After clinical examination and laboratory tests, individuals were randomly assigned to receive the
fixed-dose combination (73) or placebo (73), five capsules per day for 48 to 72 hours. The primary efficacy endpoint
was the sum of the scores of 10 symptoms on a four-point Likert-type scale. To evaluate treatment safety, the
occurrence of adverse events was also measured.
Results: Mean age was 33.5 (±9.5) years in the placebo group and 33.8 (±11.5) in the treatment group. There were
55 women and 18 men in the placebo group, and 46 women and 27 men in the treatment group. Comparison of
overall symptom scores in the two groups revealed a significantly greater reduction in the treatment group than in
the placebo group (p = 0.015). Analysis at the first 13 dose intervals (± 66 h of treatment) showed a greater
reduction of symptom scores in the treatment group than in the placebo group (p < 0.05). The number and
distribution of adverse events were similar in both groups.
Conclusion: A fixed-dose combination of paracetamol, chlorphenamine and phenylephrine was safe and more
effective than placebo in the symptomatic treatment of the common cold or flu-like syndrome in adults.
Trial registration: NCT01389518
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Background
Acute respiratory infections are highly prevalent in the
population, with the common cold, flu-like syndromes,
tracheobronchitis, sinusitis, laryngitis and pneumonias
being particularly important. When the aetiology is pre-
sumably bacterial, treatment is based on the use of antibi-
otics and medication for symptomatic relief. However, the
most common clinical entities, the common cold and the
flu-like syndrome, have a viral aetiology, for which symp-
tomatic treatment remains, in most cases, the standard
recommendation.
The common cold is the most frequently encountered
disease in medical practice [1]. It affects most adults, on
average two to four times a year, and accounts for up to
40% of work absences among the economically active
population in the United States [2].
This syndrome affects the upper airways, sometimes in
association with low-grade fever and systemic symptoms,
and usually presents with at least two of the following
symptoms: cough, dysphonia, throat discomfort, sore
throat, nasal congestion, rhinorrhoea, sneezing, headaches,
myalgia and fever [3]. Symptoms usually peak at 2 to
3 days and have a mean duration of 7 to 10 days [4]. This
definition has been prospectively validated in other studies
and is that most frequently used in clinical studies of
patients with the common cold [5]. Although most
cases are caused by the rhinovirus, other agents may
be involved, such as the respiratory syncytial virus,
adenovirus, coronavirus, and influenza and parainfluenza
viruses [6].
Flu-like syndrome is characterized by sudden onset
of fever, headache, cough, sore throat, myalgia, nasal
congestion, weakness and loss of appetite [4]. Compli-
cations, such as pneumonia, otitis and sinusitis, may
occur [7].
Some of the medications studied for the treatment of
the common cold are antihistamines, anticholinergics,
alpha-adrenergic agonists, membrane stabilizers, non-
steroidal anti-inflammatory drugs, vitamin C, glucocor-
ticoids, zinc, herbal medications and alpha-interferon.
Clinical trials of high-dose vitamin C have not found
any benefits in the treatment of the common cold [8].
Recent studies of Echinacea purpurea, a herbal medicine,
did not find any clinical benefits for patients with the
common cold [9-12]. The results of meta-analyses about
the efficacy of zinc are contradictory, and there is weak
evidence of its benefit in well-designed studies [13-15].
The symptomatic treatment of the common cold has
been evaluated in Cochrane meta-analyses. The first in-
cluded 32 studies with a total of 8930 patients and investi-
gated the administration of antihistamines in the common
cold. Results showed that monotherapy did not improve
symptoms in either children or adults [16]. The combined
use of antihistamines and decongestants may alleviate
symptoms in adults, but results are heterogeneous [15,17].
Another meta-analysis investigated the use of nasal
decongestants in the common cold in 286 adults, and
found no benefit for the relief of nasal congestion
[15,18]. Another recent meta-analysis [19] suggests that
a triple combination of antihistamine, decongestant and
analgesic provided some general benefit in adults and
older children.
Most cases of influenza require the use of drugs for
symptomatic relief [1,20]. In clinical practice, treatment
directed to the aetiological agent is not routine, but
became considerably more frequent after the H1N1
pandemic in 2009 [21].
Therefore, patients continue to use medications that
produce symptomatic relief because of the epidemiological
relevance and the intensity of symptoms of flu-like
syndromes and the common cold.
This study evaluated the efficacy and safety of a fixed-
dose combination of paracetamol, chlorphenamine and
phenylephrine in the symptomatic treatment of the com-
mon cold and flu-like syndromes by analysing symptom
score reductions during and after treatment, duration of
symptoms, return to usual activities and adverse events
in both groups.
No other randomized clinical trial (RCT) evaluated the
safety and efficacy of this specific fixed-dose combination
for the common cold in adults. This was the first RCT
conducted in Brazil designed to also assess adverse
cardiovascular effects of phenylephrine.
Methods
This phase III, prospective, randomized, double-blind,
placebo-controlled clinical trial enrolled volunteers
recruited by means of posters displayed in Hospital de
Clínicas de Porto Alegre (HCPA) and in primary care
centres in the city of Porto Alegre, Brazil, and of ads
placed in local newspapers.
Inclusion criteria
This study included volunteers of both genders, aged
18 to 60 years, with a duration of symptoms no longer
than 72 hours. The common cold was defined by the
presence of at least two of the following 10 symptoms:
sneezing, rhinorrhoea, nasal congestion, headache, my-
algia, throat discomfort, sore throat, dysphonia, cough
and fever. Symptoms should be moderate to severe on
a four-point, Likert-type symptom severity scale (0 = no
symptoms; 1 = mild; 2 = moderate; 3 = severe). Flu-like
syndrome should include fever of at least 38.1°C and
moderate to severe headache or moderate to severe
myalgia or arthralgia in the Likert-type symptom severity
scale described above.
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Exclusion criteria
Volunteers were excluded from the study if they met
any of the following criteria: pregnancy or breastfeed-
ing; known hypersensitivity to any component of the
study formulation; use of alcohol or illicit drugs; use of
monoamine oxidase (MAO) inhibitors or barbiturates;
perennial or seasonal allergic rhinitis confirmed at
screening; any current acute disease or uncontrolled
exacerbation of chronic disease; clinical evidence of
immunosuppression; vaccination against influenza up
to 1 week before inclusion; need for antiviral therapy to
treat influenza A or B infection; need for antibacterial
therapy to treat acute respiratory infection; use of medi-
cation to treat conditions acquired before inclusion for
a time shorter than two time intervals of administration
of these drugs; and participation in another clinical trial
less than 1 year before.
Sample size calculation
For a statistical power of 80%, a random error of 5%
and a response rate of 30% in the treatment group in
comparison with the placebo group, and a 50% reduction
in symptom scores after the second day of follow-up in
the placebo group, the sample size was calculated as 132
patients (66 in each group) [22]. To account for a possible
loss to follow-up of 10% of the volunteers, 146 patients
were included in the study (73 in each group).
Statistical analysis
All variables were collected and entered into the database
before randomization codes were opened. The database
was created using the Epi-INFO 3.5.1 software. SPSS 14.0
was used for statistical analyses.
All variables of interest were expressed as absolute and
relative frequencies. The Student t-test for independent
samples was used for the comparison of means for all con-
tinuous, symmetrically distributed variables. Repeated-
measures analysis of variance (ANOVA) was used for
the analysis of variance of overall score means in 11
measurements.
All randomized patients were included in the analysis
of efficacy (intention to treat). For all analyses, the level
of significance was set at p = 0.05.
Randomization and blinding
Randomization for this clinical trial was performed
using the Random Allocation Software and simple ran-
domization into two groups by means of a table of ran-
dom numbers, which generated a simple randomization
spreadsheet.
The list of random numbers was placed in a sealed en-
velope kept by the statistician responsible for analyses.
None of the authors had access to the randomization
table. The active drug and placebo capsules had
identical organoleptic characteristics. A standard label,
designed for use with both groups, contained the fol-
lowing information: name of the study, study registra-
tion number with of HCPA Research Ethics Committee,
bottle number/randomization number, and instructions
for use and storage.
Intervention
Study drug: One capsule of a fixed-dose combination of
400 mg paracetamol, 4.0 mg chlorphenamine and 4.0 mg
phenylephrine was administered according to manufac-
turer instructions [23] every 4 hours during waking hours
between 7 a.m. and 11 p.m. (five daily doses) for 2 to 3
consecutive days. Patients were instructed to use the drug
for no fewer than 2 and no more than 3 days as this
reflects best clinical practice, in which users decide the
maximum duration of use according to the intensity of
their symptoms.
Placebo: One capsule was administered every 4 hours
during waking hours between 7 a.m. and 11 p.m. (five
daily doses) for 2 to 3 consecutive days.
Each participant included in the study received a bottle
containing 15 capsules of the study drug or placebo,
depending on group allocation, and one bottle containing
12 tablets of rescue medication (500 mg paracetamol).
Procedures
The study lasted 10 days and included three clinical
visits (V1, V2 and V3) and two rounds of laboratory tests
(baseline and V2).
In addition to medical history and physical examination,
the participants underwent laboratory tests and electrocar-
diograms (ECG). Immediately afterwards, they were ran-
domly allocated to one of the two groups and received the
study drug or placebo, a diary to keep note of symptoms
and adverse events, and the rescue medication.
At the end of treatment, which lasted 2 to 3 days, the
patients returned for re-evaluation. The second visit
included medical history, clinical and physical examin-
ation, ECG and laboratory tests, as well as an analysis of
the following aspects: symptoms, using pre-defined
scales; adverse events; duration of symptoms; time to
return to usual activities; and drug intake, by counting
the capsules and tablets used.
The third and last follow-up visit took place 7 days
after the end of the treatment, when the following pa-
rameters were evaluated: persistent symptoms, according
to predefined scales; duration of symptoms; time to return
to usual activities; adverse events; and use of other
medications after stopping use of the study drug.
Group allocation was disclosed only after data had been
collected and entered into the study database, by double
and independent entry followed by a comparison of the
two datasets. The envelope containing the randomization
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table was opened in the presence of representatives of the
study sponsor and the principal investigator.
Data were collected for this clinical trial from June 2,
2009 to July 7, 2009. The clinical visits were conducted at
the HCPA Clinical Drug Research Center (NUCLIMED).
The database was checked and analysed and the final
report was written from August 8 to October 31, 2009.
Efficacy analysis
The primary endpoint was the sum of the scores of 10
common cold or flu-like syndrome symptoms evaluated
on a four-point Likert-type scale for intensity (severity):
0 = no symptoms; 1 =mild; 2 =moderate; and 3 = severe.
The maximum and minimum scores for each measure-
ment were 40 and zero respectively. This scale was used
by the physician during visits and also by the patients for
daily self-evaluation using the study diary. Participants
rated their symptoms at home before each administration
of the study drug or placebo throughout the treatment
period, so that a total of 10 to 15 measurements were
obtained.
Secondary endpoints were overall symptom duration,
time to return to usual activities, and use of rescue
medication.
Safety analysis
Drug safety was evaluated by the occurrence of adverse
events detected in clinical history, physical examination
findings, or abnormal lab results during treatment or up
to 7 days after the last dose of the medication.
All serious and non-serious adverse events were fully
documented using clinical charts, original documents,
and specific forms. In addition, all adverse events occur-
ring within 7 days of the treatment were investigated, re-
corded and compared between groups. Adverse events
were followed until their resolution or until follow-up was
classified (in writing) as complete by the investigators.
Bioethical issues
This study was approved by the Ethics Committee of the
Graduate Studies and Research Group of Hospital de
Clínicas de Porto Alegre (HCPA). All participants were
volunteers, and all procedures for this study were started
only after participants had read and signed an informed
consent form approved by the HCPA Research Ethics
Committee.
Results
This study included 146 patients randomly distributed
into two groups (placebo and treatment) of 73 patients
each (Figure 1).
Table 1 shows the baseline characteristics of the study
sample. The groups were homogeneous except for weight,
which was greater in the treatment group. Mean (±SD)
time between V1 and V2 was 72.9 (±10.5) hours, with no
significant between-group differences (p = 0.919).
Figure 1 Study flowchart.
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Efficacy analysis
Mean symptom scores were calculated for both groups
at V1 and V2 (before and after treatment), without any
data loss, as 100% of the patients attended both visits.
At V1, the mean (±SD) overall symptom score was
14.23 (±4.09) in the placebo group and 14.09 (±3.78) in
the treatment group, which demonstrates similarity
between groups at that time point. At V2, the overall
symptom score was markedly reduced in both groups,
from 14.23 to 4.64 in the placebo group and from 14.09
to 3.54 in the treatment group. Separate comparison of
mean overall scores of symptoms as evaluated by physi-
cians at V2 showed that scores were lower in the treat-
ment group, with a trend toward statistical significance
(p = 0.063). Comparison of the overall score reduction
induced by treatment or placebo (V1-V2) in the two
groups revealed that this reduction was significantly
greater in the treatment group (p = 0.015) (Figure 2).
The total number of days with reported symptoms was
measured in 55 and 49 subjects of the placebo and treat-
ment groups respectively. The mean (+SD) number of
days with symptoms was 7.5 (+5.3) days in the placebo
group and 5.9 (+3.4) days in the active treatment group
(p = 0.08).
Analysis of the symptom score curves of both groups
revealed that the curves separated after the second dose.
ANOVA showed that, during the first 11 dose intervals
(Figure 3), which corresponded to at least 52 hours of
treatment, a statistically significant reduction in symptom
scores occurred in the treatment group in comparison
with the placebo group (p < 0.049). ANOVA including the
first 13 dose intervals, a time corresponding to 66 hours of
treatment (including hours of sleep), also revealed a reduc-
tion in symptom scores in the treatment group, again with
a statistically significant difference (p ≤ 0.05).
To evaluate the use of rescue medication (500 mg
paracetamol), the mean number of tablets taken and the
total number of patients that used the rescue medication
in each group were compared. The mean number of tab-
lets taken was lower in the treatment group than in the
placebo group (0.78 [±1.88] vs. 1.3 [±1.72]; p = 0.002). A
greater percentage of patients in the placebo group used
rescue paracetamol (50.7%) than in the treatment group
(25%), and this difference was statistically significant
(chi-square test, p = 0.001).
Mean axillary temperature was not statistically different
between groups, and there were no differences between
axillary temperature values at V1 and V2.
Safety analysis
The overall incidence of patient-reported adverse events
was 34 events in the placebo group and 39 in the treatment
Table 1 Baseline characteristics of the study population









Height (m) 1.64 (±0.08) 1.67 (±0.11)
BMI (kg/m2) 25.28 (±4.29) 26.95 (±6.03)
Mean symptom score 14.23 (±4.09) 14.89 (±3.78)
Weight (kg) 68.21 (±13.18) 75.27 (±18.53)
Time from symptom onset to start of
treatment (h)
42.29 (±17.54) 46.57 (±15.65)
Figure 2 Mean symptom score before and after treatment. * Comparison between mean overall scores: Student t-test for independent
samples; ** Mean score variation in the two groups (V1-V2): Student t-test for independent samples.
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group, with no statistically significant between-group dif-
ferences (p = 0.508). Furthermore, analysis of the incidence
of specific symptoms in each group did not reveal any sta-
tistically significant differences, and the distribution of the
number of adverse events was homogeneous in the two
groups. The main adverse event reported was drowsiness
(n = 43), followed by nausea (n = 18). Overall, 110 patients
experienced some type of adverse effect in both groups.
Mean (±SD) heart rate (HR) was 76.60 (±11.04) bpm
in the treatment group and 77.36 (±12.96) bpm in the
placebo group at V1. At V2, mean HR was 76.72
(±10.53) bpm in the treatment group and 77.96 (±11.00)
bpm in the placebo group. Comparisons of HR variation
before and after treatment did not reveal any significant
between-group differences (p = 0.834).
Mean (±SD) systolic blood pressure (SBP) at V1 was
119.22 (±13.09) mmHg in the treatment group and
115.66 (±13.55) mmHg in the placebo group, and this
difference was not significant (p = 0.11). At V2, mean
SBP was 120.82 (±15.93) mmHg in the treatment group
and 114.01 (±12.29) mmHg in the placebo group, and
this difference was statistically significant (p = 0.004).
Comparison of BP variation before and after treatment
did not reveal any significant differences (p = 0.092).
Laboratory test results did not show any clinically
relevant changes in relation to any of the study variables.
β-HCG, urinalysis (density, pH, proteinuria, glycosuria, ke-
tonuria, bilirubin, urobilinogen, haemoglobinuria, nitrite,
leukocyte esterase) and FBC results were not significantly
different between V1 and V2.
No serious adverse events were recorded during the
study, and no patients withdrew from the study due to ad-
verse events. The reasons for exclusion from the sample
are shown in Figure 1.
Discussion
This was the first randomized, double-blind clinical trial
to demonstrate the efficacy of a fixed-dose combination
of 400 mg paracetamol, 4.0 mg chlorphenamine and
4.0 mg phenylephrine in reducing flu-like symptoms by
means of both objective evaluation of symptoms by the
investigators and subjective reports provided by patients.
The evaluation of rescue paracetamol use as a dichotom-
ous variable showed that 50.7% of patients in the
placebo group versus 25% in the treatment group used
the rescue medication. This difference indicates that for
every four patients treated with the study drug, one did
not take rescue paracetamol (NNT = 4). This reduction
of the rate of rescue medication use is an index of anal-
gesic efficacy and demonstrates that patients with flu-
like symptoms actually seek an alternative form of relief
when the medication they are taking is not efficacious.
Time to freedom from symptoms was lower in the
treatment group than in the placebo group, although
the difference did not reach statistical significance.
The comparison of baseline and final scores revealed
that both groups experienced a major reduction in the
total symptom score, both as assessed by the investiga-
tors and as reported by the patients themselves, a result
that may be attributed to the fact that the common cold
is a self-limiting disease. The rapid symptom reduction
precludes demonstration of any between-group differences
at the end of the treatment (48 to 72 hours). Therefore,
the fact that treatment group had a statistically significant
difference from the placebo group at this time point
supports the efficacy of the study drug.
Evaluation of patient-reported symptom scores (study
diary) by ANOVA showed a statistically significant re-
duction in symptom scores in the treatment group as
Figure 3 Overall patient-reported score in each group (treatment vs. placebo) at 11-dose intervals. * Repeated-measures analysis of
variance (ANOVA).
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compared with the placebo groups (p ≤ 0.05). This dif-
ference of up to 3 points in symptom scores was con-
stant during the first 13 doses and translates into a
trend towards a 1.5-day reduction in the total duration
of symptoms. If confirmed in larger studies, this finding
could have a major impact on the population, given the
high annual incidence of flu-like syndrome and the
large number of users of over-the-counter medication
for symptomatic relief of its symptoms worldwide. After
the 13th dose, symptom scores were very low and similar
between groups, which confirms the self-limiting char-
acteristic of the disease and made it difficult for patients
to assign scores to their symptoms. According to the
study protocol, patients did not have to take the medi-
cation (either active or placebo) for more than 10 doses
(corresponding to 48 hours, or 2 days). This explains
the reduction in the number of cases for analysis after
the 13th dose.
Analysis of the HR variation attributable to treatment
revealed that the active formulation did not increase
HR. Furthermore, treatment did not increase systolic
BP. A small between-group difference in this variable
was already detectable at baseline. Although not signifi-
cant, patients in the treatment group had higher baseline
mean values (a 4.44 mmHg difference), which may be
attributable to randomization. However, all mean values in
both groups were within normal limits both at baseline
and after treatment. The increase in mean systolic BP
attributable to treatment with the active formulation
was only 1.6 mmHg; therefore, there was no increase in
sensitivity to sympathomimetic agents, and the response
after treatment in this group was not more intense than in
the placebo group. The absence of patient- or investigator-
detected effects on cardiovascular parameters, HR, or SBP
suggests that the study drug did not increase cardiovas-
cular risk. Hence, this RCT adds valuable safety data,
particularly in regard to the effects of the decongestant
agent phenylephrine on blood pressure, heart rate and
ECG parameters.
Some limitations of this study must be mentioned,
including the difficulties of studying a disease such as
the common cold, which is self-limited and combines
multiple symptoms with a very rapid rate of resolution.
The majority of patients were symptom-free by the 7th
day after the end of treatment. Moreover, most patients
had a low symptom score at randomization, probably
because of the generally accepted concept of at-home
recovery for flu-like illness. This limitation had a
negative influence on identification of severe disease,
which, combined with the rapid resolution of symptoms
(very low symptom score), reduces the possibility of iden-
tifying between-group differences. For these reasons, any
statistically significant differences found might be inter-
preted as having potential for clinical relevance.
Safety analysis did not reveal any clinically relevant
change in any clinical or laboratory variables at the two
time points of evaluation, whether within-group or
between-group (active vs. placebo). Furthermore, there
were no statistically significant between-group differences
in treatment-emergent adverse effects.
Conclusion
Administration of the study drug at the dose suggested
in its package insert was more efficacious than placebo in
the symptomatic treatment of the common cold or flu-
like illness. The study drug also reduced the frequency of
use of rescue medication as compared with placebo, and
was as safe as placebo. These findings suggest that a fixed-
dose combination of paracetamol, chlorphenamine and
phenylephrine may be an effective and safe alternative for
treatment of these clinical entities.
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